Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
TRIB Stock Overview
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe.
Trinity Biotech Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.34 |
52 Week High | US$3.05 |
52 Week Low | US$0.86 |
Beta | 1.32 |
1 Month Change | -2.90% |
3 Month Change | 23.50% |
1 Year Change | -55.03% |
3 Year Change | -23.43% |
5 Year Change | -77.17% |
Change since IPO | -91.63% |
Recent News & Updates
Shareholder Returns
TRIB | US Medical Equipment | US Market | |
---|---|---|---|
7D | 3.9% | 3.5% | 1.7% |
1Y | -55.0% | -25.7% | -20.4% |
Return vs Industry: TRIB underperformed the US Medical Equipment industry which returned -24% over the past year.
Return vs Market: TRIB underperformed the US Market which returned -18.8% over the past year.
Price Volatility
TRIB volatility | |
---|---|
TRIB Average Weekly Movement | 9.9% |
Medical Equipment Industry Average Movement | 10.4% |
Market Average Movement | 8.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TRIB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TRIB's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 477 | Ronan O’Caoimh | https://www.trinitybiotech.com |
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
Trinity Biotech Fundamentals Summary
TRIB fundamental statistics | |
---|---|
Market Cap | US$47.45m |
Earnings (TTM) | US$929.00k |
Revenue (TTM) | US$92.97m |
50.5x
P/E Ratio0.5x
P/S RatioIs TRIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRIB income statement (TTM) | |
---|---|
Revenue | US$92.97m |
Cost of Revenue | US$54.89m |
Gross Profit | US$38.08m |
Other Expenses | US$37.15m |
Earnings | US$929.00k |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0.027 |
Gross Margin | 40.96% |
Net Profit Margin | 1.00% |
Debt/Equity Ratio | -26,126.3% |
How did TRIB perform over the long term?
See historical performance and comparisonValuation
Is TRIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TRIB?
Other financial metrics that can be useful for relative valuation.
What is TRIB's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$47.45m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.3x |
Enterprise Value/EBITDA | 11.4x |
PEG Ratio | 0.5x |
Price to Earnings Ratio vs Peers
How does TRIB's PE Ratio compare to its peers?
TRIB PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 67.4x | ||
PDEX Pro-Dex | 31x | 72.3% | US$56.1m |
RAYT Rayont | 192.1x | n/a | US$72.1m |
DXR Daxor | 11.2x | n/a | US$53.4m |
ELMD Electromed | 35.1x | n/a | US$81.6m |
TRIB Trinity Biotech | 50.5x | 109.0% | US$47.5m |
Price-To-Earnings vs Peers: TRIB is good value based on its Price-To-Earnings Ratio (50.5x) compared to the peer average (67.4x).
Price to Earnings Ratio vs Industry
How does TRIB's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: TRIB is expensive based on its Price-To-Earnings Ratio (50.5x) compared to the US Medical Equipment industry average (34.5x)
Price to Earnings Ratio vs Fair Ratio
What is TRIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 50.5x |
Fair PE Ratio | 184x |
Price-To-Earnings vs Fair Ratio: TRIB is good value based on its Price-To-Earnings Ratio (50.5x) compared to the estimated Fair Price-To-Earnings Ratio (184x).
Share Price vs Fair Value
What is the Fair Price of TRIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TRIB ($1.34) is trading above our estimate of fair value ($1.07)
Significantly Below Fair Value: TRIB is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: TRIB is good value based on its PEG Ratio (0.5x)
Discover undervalued companies
Future Growth
How is Trinity Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
109.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRIB's forecast earnings growth (109% per year) is above the savings rate (1.9%).
Earnings vs Market: TRIB's earnings (109% per year) are forecast to grow faster than the US market (13.8% per year).
High Growth Earnings: TRIB's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TRIB's revenue (0.6% per year) is forecast to grow slower than the US market (8.3% per year).
High Growth Revenue: TRIB's revenue (0.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TRIB's Return on Equity is forecast to be low in 3 years time (18.2%).
Discover growth companies
Past Performance
How has Trinity Biotech performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
31.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRIB has a large one-off loss of $2.3M impacting its December 31 2021 financial results.
Growing Profit Margin: TRIB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: TRIB has become profitable over the past 5 years, growing earnings by 31.1% per year.
Accelerating Growth: TRIB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: TRIB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: TRIB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is Trinity Biotech's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: TRIB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TRIB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TRIB has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: TRIB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: TRIB's debt is not well covered by operating cash flow (15.9%).
Interest Coverage: TRIB's interest payments on its debt are not well covered by EBIT (1.3x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Trinity Biotech current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRIB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRIB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: TRIB is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TRIB has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
7.2yrs
Average management tenure
CEO
Ronan O’Caoimh (65 yo)
13.67yrs
Tenure
US$643,000
Compensation
Mr. Ronan O'Caoimh co-founded Trinity Biotech PLC in June 1992 and has been its Chief Executive Officer since October 2008. Mr. O'Caoimh served as Chief Executive Officer of Trinity Biotech PLC from March...
CEO Compensation Analysis
Compensation vs Market: Ronan's total compensation ($USD643.00K) is about average for companies of similar size in the US market ($USD752.76K).
Compensation vs Earnings: Ronan's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: TRIB's management team is seasoned and experienced (7.2 years average tenure).
Board Members
Experienced Board: TRIB's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 67.3%.
Top Shareholders
Company Information
Trinity Biotech plc's employee growth, exchange listings and data sources
Key Information
- Name: Trinity Biotech plc
- Ticker: TRIB
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$47.452m
- Shares outstanding: 34.97m
- Website: https://www.trinitybiotech.com
Number of Employees
Location
- Trinity Biotech plc
- IDA Business Park
- Bray
- Co. Wicklow
- Ireland
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/28 00:00 |
End of Day Share Price | 2022/06/28 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.